Sublingual GLP-1 polypeptide freeze-dried powder and preparation method thereof
Through the preparation method of lyophilized powder preparation, combined with lipid protectors and antioxidants, the problem of low stability and bioavailability of GLP-1 polypeptide drugs in sublingual containers is solved, and higher drug stability is achieved and bioavailability, simplifying the preparation process and reducing costs.
Patent Information
- Application Number
- CN202411294651.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing GLP-1 polypeptide drugs have poor stability when taken sublingually, and cannot effectively solve the problems of polypeptide polymerization and oxidation reactions in the preservation and transportation of drugs, resulting in low bioavailability and painful and adverse reactions in the administration mode.
In the form of a lyophilized powder preparation, stable drugs are prepared by mixing GLP-1 polypeptide raw materials with lipid protecting agents, stabilizers, antioxidants and pH regulators and pre-freeze and multiple freeze-drying treatments. Sublingually contained GLP-1 polypeptide lyophilized powder preparations to improve the stability and antioxidant activity of the drug.
It improves the stability and bioavailability of GLP-1 polypeptide drugs, reduces the risk of inactivation of drugs in storage and transportation, simplifies the preparation process, does not require large-scale equipment, facilitates quality control, and reduces the storage cost of drugs.
Smart Images

Figure CN119074900A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the technical field of polypeptide drugs, and in particular relates to a sublingual GLP-1 polypeptide lyophilized powder and a preparation method thereof. Background Art
[0002] Diabetes is a chronic metabolic disease characterized by high blood sugar levels. It has become one of the nine leading causes of death worldwide and poses a great threat to human life and health. Type II diabetes is a chronic disease caused by insufficient insulin use or reduced efficiency. Most patients with type II diabetes are obese. Further weight gain during insulin injection therapy will aggravate the patient's metabolic disorders and diabetes-related complications, leading to the risk of death.
[0003] Glucagon-like peptide-1 (GLP-1) is a multifunctional peptide hormone secreted by L cells in the ileum and colon. Among its many metabolic effects, GLP-1 has become a new target for the treatment of type II diabetes by stimulating insulin secretion in a glucose-dependent manner, slowing gastric emptying, suppressing appetite, and increasing sodium excretion and urination. However, after GLP-1 is secreted into the blood, it is rapidly decomposed and inactivated by dipeptidyl peptidase 4 (DPP-4), and its half-life in the body is only 2 minutes, which limits its application in hypoglycemic treatment. GLP-1 peptides can have similar effects to GLP-1, and at the same time, due to structural differences with natural GLP-1, the duration of action can be enhanced. The weight loss effect of GLP-1 peptide drug therapy is very beneficial to diabetic patients. More importantly, its cardiovascular benefits provide excellent clinical compliance for long-term GLP-1 treatment.
[0004] In 2005, Exenatide was approved by the U.S. Food and Drug Administration (FDA) for use in the auxiliary control of blood sugar in patients with type II diabetes who cannot be controlled by oral hypoglycemic drugs. Exenatide is administered by subcutaneous injection and can have a good effect in inhibiting the increase of blood sugar. However, because subcutaneous injection causes pain at the injection site and low bioavailability, GLP-1 peptide drugs are stored in the form of aqueous solutions, which have poor stability, short shelf life, and require storage in a low-temperature environment.
[0005] In 2019, semaglutide oral tablets were approved for marketing by the U.S. Food and Drug Administration (FDA). They are stored in tablet form, which greatly reduces the storage cost of peptide drug reagents and only needs to be stored at room temperature of 20-25°C. However, the drug needs to be taken orally by the patient, enter the digestive system through the mouth, and then be absorbed by the intestinal blood vessels. This process makes the drug's efficacy slow to take effect, and the drug is easily inactivated by gastric acid and digestive tract enzymes in the stomach. At the same time, the oral administration method will cause a small number of patients to experience adverse conditions such as abdominal pain and fever.
[0006] Currently, most GLP-1 peptide therapeutic drugs on the market are stored in the form of injections, but they all have more or less shortcomings. In view of the above-mentioned problems, the defects of previous drug administration methods can be well improved through sublingual administration. Sublingual GLP-1 peptide drugs can directly enter the blood circulation through the sublingual vein, avoiding first-pass metabolism in the intestine and liver, and can improve bioavailability. GLP-1 peptide therapeutic drugs are subject to polypeptide polymerization and oxidation reactions during storage, which are more likely to occur in the form of injections, and the preservative is inconvenient to transport.
[0007] Therefore, there is an urgent need to provide a method for preparing a lyophilized powder of a sublingual glucagon-like peptide-1 (GLP-1) polypeptide drug that can be stably stored. Summary of the invention
[0008] The purpose of the present application is to provide a sublingual GLP-1 polypeptide lyophilized powder and a preparation method thereof, aiming to solve the problem that the sublingual GLP-1 polypeptide drug in the prior art has poor stability and cannot be used.
[0009] In order to achieve the above application purpose, the technical solution adopted in this application is as follows:
[0010] In a first aspect, the present application provides a sublingual GLP-1 polypeptide preparation raw material, which comprises the following components in the following weight percentages, based on the total weight of the sublingual GLP-1 polypeptide preparation raw material as 100%:
[0011]
[0012]
[0013] In some embodiments, the GLP-1 polypeptide raw material drug comprises any one of exenatide, liraglutide and semaglutide.
[0014] In some embodiments, the lipid protectant dressing comprises at least one of lecithin, fatty acid glycerol, and distearoylphosphatidylglycerol.
[0015] In some embodiments, the stabilizer dressing comprises at least one of mannitol, sorbitol, trehalose, and pullulan.
[0016] In some embodiments, the amphiphilic polymer dressing includes at least one of polyethylene glycol 400, polyethylene glycol polycaprolactone, and polyethylene glycol chlorinated polyethylene.
[0017] In some embodiments, the antioxidant comprises at least one of methionine, sodium sulfite, and N-acetylmethionine.
[0018] In some embodiments, the pH adjuster includes sodium hydroxide with a mass percentage of 10% or hydrochloric acid with a mass percentage of 10%.
[0019] In a second aspect, the present application provides a sublingual GLP-1 polypeptide drug lyophilized powder preparation, wherein the sublingual GLP-1 polypeptide drug lyophilized powder preparation is prepared using the above-mentioned sublingual GLP-1 polypeptide preparation raw material as a raw material.
[0020] In a third aspect, the present application provides a method for preparing a sublingual GLP-1 polypeptide drug lyophilized powder preparation, comprising the following steps:
[0021] Obtaining raw materials according to the above-mentioned sublingual GLP-1 polypeptide drug lyophilized powder preparation;
[0022] Completely dissolving the GLP-1 polypeptide raw material drug in water to obtain a GLP-1 polypeptide raw material drug solution;
[0023] The GLP-1 polypeptide raw material drug solution is mixed with a lipid protective agent dressing, a stabilizer dressing, an amphiphilic polymer dressing, and an antioxidant, and a pH regulator is used to adjust the pH to 7.5-8.0 to obtain a mixed solution;
[0024] The mixed solution is first pre-frozen and then subjected to multiple freeze-drying treatments to obtain a sublingual GLP-1 polypeptide drug freeze-dried powder preparation.
[0025] In some embodiments, the multiple freeze-drying processes include the following steps:
[0026] Lower the chamber temperature of the vacuum freeze dryer to -50°C and pre-evacuate for 30 minutes to obtain a vacuum degree of ≤30mTorr;
[0027] The pre-frozen mixed solution was vacuum freeze-dried at -50°C for 240 minutes, then the temperature was raised from -50°C to -25°C, vacuum freeze-dried for 10 minutes, and then vacuum freeze-dried at -25°C for 120 minutes; then the temperature was raised from -25°C to 4°C, vacuum freeze-dried for 15 minutes, and then vacuum freeze-dried at 4°C for 90 minutes; then the temperature was raised from 4°C to 25°C, vacuum freeze-dried for 15 minutes, and then vacuum freeze-dried at 4°C for 60 minutes.
[0028] In some embodiments, in the step of pre-freezing the mixed solution, the pre-freezing temperature is -80°C and the time is 30 minutes.
[0029] The sublingual GLP-1 polypeptide preparation raw materials provided in the first aspect of the present application are based on GLP-1 polypeptide raw material drugs, including lipid protectant dressings, stabilizer dressings, amphiphilic polymer dressings, antioxidants, pH adjusters, phosphate buffer and water. The preparation formula is optimized to make the GLP-1 polypeptide drug more stable, have antioxidant effects to prevent changes in drug activity, and are conducive to wide use.
[0030] The second aspect of the present application provides a sublingual GLP-1 polypeptide drug lyophilized powder preparation. The provided sublingual GLP-1 polypeptide drug lyophilized powder preparation is prepared using the above-mentioned sublingual GLP-1 polypeptide preparation raw materials as raw materials. The obtained sublingual GLP-1 polypeptide drug lyophilized powder preparation has good stability and strong antioxidant activity, which is conducive to wide application.
[0031] The third aspect of the present application provides a method for preparing a sublingual GLP-1 polypeptide drug lyophilized powder preparation. In the preparation method, the raw materials are first mixed evenly and then pre-frozen, and then processed using a programmed gradient freeze-drying method. The method is easy to operate and facilitates quality control; the preparation process is simple and does not require the use of large-scale instruments and equipment. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0033] Figure 1 This is the content analysis of sublingual GLP-1 lyophilized powder at different time points provided in the examples of the present application.
[0034] Figure 2 This is the effect of sublingual GLP-1 polypeptide on blood glucose in Type II diabetic rats provided in the examples of the present application. DETAILED DESCRIPTION
[0035] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.
[0036] In this application, the term "and / or" describes the association relationship of associated objects, indicating that there may be three relationships. For example, A and / or B can mean: A exists alone, A and B exist at the same time, and B exists alone. A and B can be singular or plural. The character " / " generally indicates that the associated objects are in an "or" relationship.
[0037] In this application, "at least one" means one or more, and "plurality" means two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single items or plural items. For example, "at least one of a, b, or c", or "at least one of a, b, and c" can all mean: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, c can be single or multiple, respectively.
[0038] It should be understood that in the various embodiments of the present application, the size of the serial numbers of the above-mentioned processes does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.
[0039] The terms used in the embodiments of the present application are only for the purpose of describing specific embodiments, and are not intended to limit the present application. The singular forms "a", "an" and "the" used in the embodiments of the present application and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.
[0040] The weight of the relevant components mentioned in the embodiment description of the present application can not only refer to the specific content of each component, but also represent the proportional relationship between the weights of the components. Therefore, as long as the content of the relevant components is proportionally enlarged or reduced according to the embodiment description of the present application, it is within the scope disclosed in the embodiment description of the present application. Specifically, the mass described in the embodiment description of the present application can be a mass unit known in the chemical industry such as μg, mg, g, kg, etc.
[0041] The terms "first" and "second" are used only for descriptive purposes to distinguish objects such as substances from each other, and should not be understood as indicating or implying relative importance or implicitly indicating the number of indicated technical features. For example, without departing from the scope of the embodiments of the present application, the first XX may also be referred to as the second XX, and similarly, the second XX may also be referred to as the first XX. Thus, features defined as "first" and "second" may explicitly or implicitly include one or more of the features.
[0042] In a first aspect, an embodiment of the present application provides a sublingual GLP-1 polypeptide preparation raw material, which comprises the following components in the following weight percentages, based on the total weight of the sublingual GLP-1 polypeptide preparation raw material as 100%:
[0043]
[0044] The sublingual GLP-1 polypeptide preparation raw materials provided in the first aspect of the embodiment of the present application are based on GLP-1 polypeptide raw material drugs, including lipid protectant dressings, stabilizer dressings, amphiphilic polymer dressings, antioxidants, pH adjusters, phosphate buffer and water. The preparation formula is optimized to make the GLP-1 polypeptide drug more stable, have antioxidant effects to prevent changes in drug activity, and are conducive to wide use.
[0045] In some embodiments, the GLP-1 polypeptide bulk drug comprises any one of exenatide, liraglutide and semaglutide. In some embodiments, the GLP-1 polypeptide bulk drug has a preparation concentration of 0.8 mg / ml before lyophilization.
[0046] In some embodiments, the lipid protectant dressing comprises at least one of lecithin, fatty acid glycerol, and distearoylphosphatidylglycerol.
[0047] In some embodiments, the stabilizer dressing comprises at least one of mannitol, sorbitol, trehalose, and pullulan.
[0048] In some embodiments, the amphiphilic polymer dressing includes at least one of polyethylene glycol 400, polyethylene glycol polycaprolactone, and polyethylene glycol chlorinated polyethylene.
[0049] In some embodiments, the antioxidant comprises at least one of methionine, sodium sulfite, and N-acetylmethionine.
[0050] In some embodiments, the pH adjuster includes sodium hydroxide with a mass percentage of 10% or hydrochloric acid with a mass percentage of 10%.
[0051] In a second aspect, the present application provides a sublingual GLP-1 polypeptide drug lyophilized powder preparation, wherein the sublingual GLP-1 polypeptide drug lyophilized powder preparation is prepared using the above-mentioned sublingual GLP-1 polypeptide preparation raw material as a raw material.
[0052] The sublingual GLP-1 polypeptide drug lyophilized powder preparation provided in the second aspect of the embodiment of the present application is prepared using the above-mentioned sublingual GLP-1 polypeptide preparation raw materials as raw materials. The obtained sublingual GLP-1 polypeptide drug lyophilized powder preparation has good stability and strong antioxidant activity, which is conducive to wide application.
[0053] In a third aspect, the present application provides a method for preparing a sublingual GLP-1 polypeptide drug lyophilized powder preparation, comprising the following steps:
[0054] S01. Obtaining raw materials according to the above-mentioned sublingual GLP-1 polypeptide drug lyophilized powder preparation;
[0055] S02. The GLP-1 polypeptide drug substance is completely dissolved in water to obtain a GLP-1 polypeptide drug substance solution;
[0056] S03. The GLP-1 polypeptide raw material drug solution is mixed with a lipid protective agent dressing, a stabilizer dressing, an amphiphilic polymer dressing, and an antioxidant, and the pH is adjusted to 7.5 to 8.0 using a pH adjuster to obtain a mixed solution;
[0057] S04. The mixed solution is first pre-frozen, and then subjected to multiple freeze-drying treatments to obtain a sublingual GLP-1 polypeptide drug lyophilized powder preparation.
[0058] The third aspect of the embodiment of the present application provides a method for preparing a sublingual GLP-1 polypeptide drug lyophilized powder preparation. In the preparation method, the raw materials are first mixed evenly and then pre-frozen, and then processed using a programmed gradient freeze-drying method. The method is easy to operate and facilitates quality control. The preparation process is simple and does not require the use of large-scale instruments and equipment.
[0059] In some embodiments, the multiple freeze-drying processes include the following steps:
[0060] Lower the chamber temperature of the vacuum freeze dryer to -50°C and pre-evacuate for 30 minutes to obtain a vacuum degree of ≤30mTorr;
[0061] The pre-frozen mixed solution was vacuum freeze-dried at -50°C for 240 minutes, then the temperature was raised from -50°C to -25°C, vacuum freeze-dried for 10 minutes, and then vacuum freeze-dried at -25°C for 120 minutes; then the temperature was raised from -25°C to 4°C, vacuum freeze-dried for 15 minutes, and then vacuum freeze-dried at 4°C for 90 minutes; then the temperature was raised from 4°C to 25°C, vacuum freeze-dried for 15 minutes, and then vacuum freeze-dried at 4°C for 60 minutes.
[0062] In some embodiments, in the step of pre-freezing the mixed solution, the pre-freezing temperature is -80°C and the time is 30 minutes.
[0063] In one embodiment, the preparation method of the sublingual GLP-1 polypeptide drug lyophilized powder preparation comprises the following steps:
[0064] Weigh 16 mg of exenatide and dissolve it in 20 ml of sterile water, stir until completely dissolved, add 100 mg of lecithin and 100 mg of distearoylphosphatidylglycerol, stir until completely dissolved, adjust the pH to 7.5-8.0, and obtain solution 1; gradually add 600 mg of mannitol and 400 mg of trehalose to solution 1, continue to stir until completely dissolved, and obtain solution 2; add 10 mg of polyethylene glycol polycaprolactone and 10 mg of sodium sulfite to solution 2, stir until completely dissolved, adjust the pH to 7.5-8.0, and obtain solution 3. After filtering and sterilizing solution 3, put it in a bottle and pre-freeze it in a -80°C refrigerator for 30 minutes. Open the vacuum freeze dryer, lower the chamber temperature to -50℃, pre-vacuum for 30 minutes, vacuum degree ≤30mTorr, continue vacuum freeze drying at -50℃ for 240 minutes, increase from -50℃ to -25℃ for 10 minutes, maintain at -25℃ for 120 minutes, increase from -25℃ to 4℃ for 15 minutes, maintain at 4℃ for 90 minutes, increase from 4℃ to 25℃ for 15 minutes, maintain at 4℃ for 60 minutes, and obtain the GLP-1 polypeptide drug lyophilized powder. When using, mix evenly with 5ml of water for injection, hold under the tongue for 5 minutes, and it has the effect of controlling blood sugar.
[0065] The following describes the invention in conjunction with specific embodiments.
[0066] Example 1
[0067] The preparation method of the sublingual GLP-1 polypeptide drug lyophilized powder preparation includes the following steps:
[0068] Weigh 16 mg of exenatide and dissolve it in 20 ml of sterile water, stir until completely dissolved, add 100 mg of lecithin and 100 mg of distearoylphosphatidylglycerol, stir until completely dissolved, adjust the pH to 7.5-8.0, and obtain solution 1; gradually add 600 mg of mannitol and 400 mg of trehalose to solution 1, continue to stir until completely dissolved, and obtain solution 2; add 10 mg of polyethylene glycol polycaprolactone and 10 mg of sodium sulfite to solution 2, stir until completely dissolved, adjust the pH to 7.5-8.0, and obtain solution 3. After filtering and sterilizing solution 3, put it in a bottle and pre-freeze it in a -80°C refrigerator for 30 minutes. Open the vacuum freeze dryer, lower the chamber temperature to -50℃, pre-vacuum for 30 minutes, vacuum degree ≤30mTorr, continue vacuum freeze drying at -50℃ for 240 minutes, increase from -50℃ to -25℃ for 10 minutes, maintain at -25℃ for 120 minutes, increase from -25℃ to 4℃ for 15 minutes, maintain at 4℃ for 90 minutes, increase from 4℃ to 25℃ for 15 minutes, maintain at 4℃ for 60 minutes, and obtain the GLP-1 polypeptide drug lyophilized powder. When using, mix evenly with 5ml of water for injection, hold under the tongue for 5 minutes, and it has the effect of controlling blood sugar.
[0069] Verification and optimization of relevant formulation factors of freeze-dried powder
[0070] Combined with the above preparation method, 16 mg of exenatide was selected and dissolved in 20 ml of sterile water, and the GLP-1 polypeptide lyophilized powder was prepared according to the experimental formula described in the table. The prepared lyophilized powder was placed in a room temperature environment for 7 days and then dissolved to detect the degradation ratio of the GLP-1 polypeptide specific main peak. The results are shown in Table 1 below:
[0071] Table 1
[0072]
[0073] According to the above experimental formulation formula, different formulation content levels were designed to determine the factors affecting stability. The factors and formulation content settings are shown in Table 2 below. The results were analyzed using Design Exper12 software, which showed that the GLP-1 polypeptide lyophilized powder prepared using the dressing formula of lecithin, distearoylphosphatidylglycerol, mannitol, trehalose, polyethylene glycol polycaprolactone, and sodium sulfite was more stable.
[0074] Table 2
[0075]
[0076]
[0077] Example 2
[0078] Stability analysis of sublingual GLP-1 lyophilized powder at room temperature for 6 months
[0079] In this embodiment, the preferred preparation method 1 is used to prepare the sublingual GLP-1 (exenatide) lyophilized powder, which is packaged in brown sealed vials and placed in a room temperature environment. The 1st day, 15th day, 30th day, 45th day, 60th day, 75th day, 90th day, 120th day, 150th day, and 180th day are selected respectively, and the exenatide content contained therein is determined and analyzed by high performance liquid chromatography. Chromatographic conditions: Chromatographic column: carbon 18 column; Mobile phase: Mobile phase A (80% NH4H2PO4 aqueous solution + 20% acetonitrile): Mobile phase B (80% acetonitrile + 20% methanol) = 37:63 (v / v); Column temperature: 35°C; Gradient elution is used, detection wavelength: 215nm; Flow rate: 1mL / min; Injection volume: 20μL. The results are as follows Figure 1 As shown, sublingual GLP-1 lyophilized powder is stable at room temperature for 6 months.
[0080] Example 3
[0081] Experimental study on hypoglycemic effect of sublingual GLP-1 (exenatide) lyophilized powder on type II diabetic rats
[0082] Ten male type 2 diabetes model rats aged 8-9 weeks were selected. After feeding for one week, they were randomly divided into two groups according to body weight, namely: Control group: normal saline was taken sublingually for 5 minutes, experimental group: exenatide was taken sublingually, dissolved in 5 ml of water for injection, and the rats were held under anesthesia for 5 minutes, with 5 rats in each group. Before administration, the rats were fasted overnight but not water-deprived. Blood glucose was tested on the rats according to the experimental grouping requirements, marked as -30min, and then divided into groups for drug administration. 30 minutes after administration, each group of rats was intraperitoneally injected with glucose at a dose of 2g / kg, and then blood glucose was tested at 6 time points including -30min, 0min, 30min, 60min, 90min, and 120min. The results are as follows Figure 2 As shown, compared with the control group, the blood glucose of rats in the experimental group that took exenatide sublingually reached a peak at 30 minutes, but gradually returned to the baseline level within 1 hour, indicating that sublingual administration of GLP-1 peptide is beneficial to controlling blood glucose in rats.
[0083] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present application should be included in the protection scope of the present application.
Claims
1. A sublingual GLP-1 polypeptide preparation raw material, characterized in that: Taking the total weight of the raw materials of the sublingual GLP-1 polypeptide preparation as 100%, the following components are included in the following weight percentages:
2. The sublingual GLP-1 polypeptide preparation raw material according to claim 1, characterized in that: The GLP-1 polypeptide raw material drug includes any one of exenatide, liraglutide and semaglutide.
3. The sublingual GLP-1 polypeptide preparation raw material according to claim 1, characterized in that: The lipid protective agent dressing comprises at least one of lecithin, fatty acid glycerol, and distearoylphosphatidylglycerol.
4. The sublingual GLP-1 polypeptide preparation raw material according to claim 1, characterized in that: The stabilizer dressing includes at least one of mannitol, sorbitol, trehalose and pullulan.
5. The sublingual GLP-1 polypeptide preparation raw material according to claim 1, characterized in that: The amphiphilic polymer dressing includes at least one of polyethylene glycol 400, polyethylene glycol polycaprolactone, and polyethylene glycol chlorinated polyethylene.
6. The sublingual GLP-1 polypeptide preparation raw material according to claim 1, characterized in that: The antioxidant includes at least one of methionine, sodium sulfite, and N-acetylmethionine; The pH regulator includes sodium hydroxide with a mass percentage concentration of 10% or hydrochloric acid with a mass percentage concentration of 10%.
7. A sublingual GLP-1 polypeptide drug lyophilized powder preparation, characterized in that: The sublingual GLP-1 polypeptide drug lyophilized powder preparation is prepared using the sublingual GLP-1 polypeptide preparation raw material according to any one of claims 1 to 6 as a raw material.
8. A method for preparing a sublingual GLP-1 polypeptide drug lyophilized powder preparation, characterized in that: The steps include: Obtaining raw materials according to the sublingual GLP-1 polypeptide drug lyophilized powder preparation according to any one of claims 1 to 6; Completely dissolving the GLP-1 polypeptide raw material drug in water to obtain a GLP-1 polypeptide raw material drug solution; The GLP-1 polypeptide raw material drug solution is mixed with a lipid protective agent dressing, a stabilizer dressing, an amphiphilic polymer dressing, and an antioxidant, and a pH regulator is used to adjust the pH to 7.5-8.0 to obtain a mixed solution; The mixed solution is first pre-frozen and then subjected to multiple freeze-drying treatments to obtain a sublingual GLP-1 polypeptide drug freeze-dried powder preparation.
9. The method for preparing the sublingual GLP-1 polypeptide drug lyophilized powder preparation according to claim 8, characterized in that: The multiple freeze-drying process comprises the following steps: Lower the chamber temperature of the vacuum freeze dryer to -50°C and pre-evacuate for 30 minutes to obtain a vacuum degree of ≤30mTorr; The pre-frozen mixed solution was vacuum freeze-dried at -50°C for 240 minutes, then the temperature was raised from -50°C to -25°C, vacuum freeze-dried for 10 minutes, and then vacuum freeze-dried at -25°C for 120 minutes; then the temperature was raised from -25°C to 4°C, vacuum freeze-dried for 15 minutes, and then vacuum freeze-dried at 4°C for 90 minutes; then the temperature was raised from 4°C to 25°C, vacuum freeze-dried for 15 minutes, and then vacuum freeze-dried at 4°C for 60 minutes.
10. The method for preparing the sublingual GLP-1 polypeptide drug lyophilized powder preparation according to claim 8, characterized in that: In the step of pre-freezing the mixed solution, the pre-freezing temperature is -80°C and the time is 30 minutes.
